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Clinical PerspectiveWhat Is New?This research revealed a wide spectrum of genetic variants and high incidence of novel pathogenic variants using a focused next‐generation sequencing strategy in a cohort of 102 patients with left ventricular noncompaction.What Are the Clinical Implications?The presence of a pathogenic variant was an independent risk factor for death, heart transplantation, or implantable cardioverter‐defibrillator insertion in patients with left ventricular noncompaction, and the prognosis was even worse in patients with double pathogenic variants or *TAZ* variants.

Introduction {#jah32477-sec-0008}
============

Left ventricular noncompaction (LVNC) was originally described as cross‐linked infantile cardiomyopathy with poor prognosis[1](#jah32477-bib-0001){ref-type="ref"} but has since been classified as a primary genetic cardiomyopathy by the American Heart Association.[2](#jah32477-bib-0002){ref-type="ref"} LVNC is characterized by a pattern of prominent trabecular meshwork and deep intertrabecular recesses communicating with the left ventricular cavity. LVNC is postulated to be caused by an arrest of the normal process of intrauterine endomyocardial morphogenesis. LVNC may be a distinct disorder but also may be associated with other cardiomyopathies.[2](#jah32477-bib-0002){ref-type="ref"}, [3](#jah32477-bib-0003){ref-type="ref"}, [4](#jah32477-bib-0004){ref-type="ref"}, [5](#jah32477-bib-0005){ref-type="ref"}, [6](#jah32477-bib-0006){ref-type="ref"}, [7](#jah32477-bib-0007){ref-type="ref"} With the development of sequencing technologies, multiple gene variants have been found related to LVNC, but the genetics of LVNC have not been fully evaluated. Previous studies have shown that sarcomere gene variants likely play an important role in patients with LVNC[8](#jah32477-bib-0008){ref-type="ref"} but do not predict clinical phenotype.[9](#jah32477-bib-0009){ref-type="ref"} Next‐generation sequencing (NGS) was used recently because of the ability to investigate multiple genes at reasonable cost. The aim of this study was to investigate the genetic landscape of LVNC and to identify genotype--phenotype correlations in the largest cohort of well‐phenotyped Japanese LVNC patients.

Methods {#jah32477-sec-0009}
=======

Clinical Evaluation {#jah32477-sec-0010}
-------------------

Unrelated childhood patients were recruited from 2001 to 2016 from 61 Japanese hospitals with divisions of pediatric cardiology. A total of 102 patients with LVNC were included in this study. Three patients had Barth syndrome; none had neuromuscular disorders. In addition, patients with congenital heart disease that induced significant hemodynamic changes or with insufficient clinical information were excluded. Clinical evaluation consisted of clinical presentation and symptoms; a personal and family history (patient\'s biological family members showed existence of any cardiomyopathy disease, not only LVNC but also other cardiomyopathy or family members \[parents or brother sisters\]), arrhythmia, thromboembolism, ECG, 2‐dimensional Doppler, and color Doppler echocardiography. The diagnosis of heart failure was based on clinical symptoms of feeding difficulty, tachypnea, and cyanosis and findings of decreased left ventricular ejection fraction (LVEF) in the left ventricle on echocardiography and cardiomegaly on chest x‐ray. A diagnosis of LVNC was made according to (1) the characteristic 2‐layered appearance of the myocardium, with an increased N/C ratio (N/C\>2.0) at end‐diastole and the disease process observed in ≥1 ventricular wall segment and (2) multiple deep intertrabecular recesses communicating with the ventricular cavity, as demonstrated by color Doppler imaging.[3](#jah32477-bib-0003){ref-type="ref"}

Informed consent was obtained from all patients' parents, according to institutional guidelines. This study protocol conforms to the ethics guidelines of the 1975 Declaration of Helsinki, as reflected in a priori approval by the research ethics committee of University of Toyama, Japan.

Mutation Screening {#jah32477-sec-0011}
------------------

Genomic DNA was extracted from whole blood using a QuickGene DNA whole blood kit S (Kurabo). NGS of 73 cardiac disorder--related genes associated with cardiomyopathies and channelopathies (Table [S1](#jah32477-sup-0001){ref-type="supplementary-material"}) was performed using an IonPGM system (Life Technologies). This custom panel utilized 2 separate polymerase chain reaction primer pools, yielding a total of 1870 amplicons and used to generate target amplicon libraries. Genomic DNA samples were polymerase chain reaction--amplified using the custom panel and an Ion AmpliSeq Library Kit v2.0 (Life Technologies, Carlsbad, CA). Individual samples were labeled using an Ion Xpress Barcode Adapters Kit (Life Technologies) and then pooled at equimolar concentrations. Emulsion polymerase chain reaction and ion sphere particle enrichment were performed using the Ion PGM HiQ OT2 Kit (Life Technologies), according to the manufacturer\'s instructions. Ion sphere particles were loaded onto a 316 chip and sequenced using an Ion PGM HiQ Sequencing Kit (Life Technologies).

Data Analysis and Variant Classification {#jah32477-sec-0012}
----------------------------------------

Torrent Suite and Ion Reporter software version 5.0 (Life Technologies) were used to perform primary, secondary, and tertiary analyses, including optimized signal processing, base calling, sequence alignment, and variant analysis. The allelic frequency of all detected variants was determined using the Exome Aggregation Consortium (ExAC) East Asian database and the Human Genetic Variation Database (HGVD), which contains data for 1208 Japanese persons.[10](#jah32477-bib-0010){ref-type="ref"} Rare variants such as those single‐nucleotide polymorphisms with a minor allele frequency (MAF) below some threshold in the combined set of cases and controls were selected.[11](#jah32477-bib-0011){ref-type="ref"} All variants with a MAF ≥0.05% among the ExAC East Asian and HGVD populations were filtered out.[12](#jah32477-bib-0012){ref-type="ref"}, [13](#jah32477-bib-0013){ref-type="ref"} We utilized 7 different in silico predictive algorithms to improve the accuracy of evaluating the pathogenicity of the remaining variants: FATHMM, SIFT, PROVEAN, Align GVGD, MutationTaster2, PolyPhen2, and CADD (URLs listed in Table [S2](#jah32477-sup-0001){ref-type="supplementary-material"}). Variants predicted to be deleterious or pathogenic by at least 5 of the 7 in silico algorithms were considered likely pathogenic. The pathogenicity of the detected variant was based on the guidelines of the American College of Medical Genetics and Genomics.[13](#jah32477-bib-0013){ref-type="ref"}

Sanger Sequencing {#jah32477-sec-0013}
-----------------

For all candidate pathogenic variants that passed these selection criteria, Sanger sequencing was used to validate the NGS results. The nucleotide sequences of amplified fragments were analyzed by direct sequencing in both directions using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems), and sequence analysis was performed using an ABI 3130xl automated sequencer (Applied Biosystems).

Assessment of the Frequency of Rare Variants in Control Population Data {#jah32477-sec-0014}
-----------------------------------------------------------------------

Differences in proportions of rare variants versus controls from the ExAC East Asian and HGVD data were assessed using the Fisher exact test, with *P*\<0.05 considered statistically significant. Potential pathogenicity of the variants was evaluated based on allele frequency, as recommended by recent guidelines for interpreting sequence variants.[13](#jah32477-bib-0013){ref-type="ref"}

Gene‐Based Collapsing Test {#jah32477-sec-0015}
--------------------------

We used a genic collapsing test to confer risk genes of LVNC.[14](#jah32477-bib-0014){ref-type="ref"}, [15](#jah32477-bib-0015){ref-type="ref"} Each gene was indicated as carrying or not carrying a "qualifying" variant. A *qualifying variant* was defined as a variant with an MAF cutoff of \<0.05% among the ExAC East Asian population. *Qualified variants* were defined as nonsynonymous, frameshift, and splice‐site variants.

Statistical Analysis {#jah32477-sec-0016}
--------------------

Statistical analysis was performed with SPSS (version 24; IBM Corp) software and R software. The unpaired *t* test or the χ^2^ test was used to compare variables. *P*\<0.05 was considered statistically significant. Important prognostic factors were used in the univariate analysis and then in Firth regression using R software.[16](#jah32477-bib-0016){ref-type="ref"} The event‐free rate for the combined end point of death, heart transplantation (HT), or implantable cardioverter‐defibrillator (ICD) insertion was calculated by the Kaplan‐Meier method and compared using the log‐rank test. The Fisher exact test was performed for each gene in collapsing analysis with a nominal significance level \<1.37×10^−4^ according to Bonferroni correction for the number of assessable genes.

Results {#jah32477-sec-0017}
=======

Baseline Clinical Characteristics {#jah32477-sec-0018}
---------------------------------

A total of 102 patients were enrolled in this study; 54 were male and 48 were female, with an age range from fetus to 12 years (mean age: 1.8±0.4 years; Table [1](#jah32477-tbl-0001){ref-type="table-wrap"}). Pathogenic variants were identified in 39 patients (38%) who presented with a much earlier age of onset and lower LVEF (*P*\<0.05) than those without pathogenic variants. The majority (76.9%) of patients with pathogenic variants presented with congestive heart failure at diagnosis. We divided the LVNC patients into 2 types: those with systolic dysfunction (n=63) and those without systolic dysfunction (n=39). Pathogenic variants were more commonly detected in patients with systolic dysfunction (31/63, 49%) than in those without (9/39, 23%; *P*=0.012). Family history was more common in patients with pathogenic variants but did not reach statistical significance. Survival analysis showed that patients with pathogenic variants had worse prognosis than patients without; 26% of the patients with pathogenic variants died or underwent HT or ICD insertion (Figure [1](#jah32477-fig-0001){ref-type="fig"}).

###### 

Characteristics of Patients With and Without Pathogenic Mutations

                            P+ (n=39)   P− (n=63)   *P* Value
  ------------------------- ----------- ----------- -----------
  Sex, male:female          18:21       34:27       0.54
  Age at onset, y           0.45±0.2    2.7±0.6     0.003
  CHF at diagnosis, n (%)   30 (76.9)   32 (50.8)   0.01
  Family history, n (%)     12 (30.8)   12 (19)     0.81
  LVEF, %                   37±2.0      46.3±3.0    0.01
  LVDD *z* score            1.59±0.18   1.44±0.56   0.79

CHF indicates congestive heart failure; LVEF, left ventricular ejection fraction; LVDD, left ventricular end‐diastolic dimension; P+, patients with pathogenic mutations; P−, patients with no or nonpathogenic mutations.

![Event‐free survival to the combined end point of death, heart transplantation, and implantable cardioverter‐defibrillator insertion of patients with double pathogenic, pathogenic, and nonpathogenic mutations.](JAH3-6-e006210-g001){#jah32477-fig-0001}

### Genetic analysis {#jah32477-sec-0019}

NGS of samples from the 102 patients yielded 540 830±11 986 sequence reads per person. The mean read length per sample was 163.6±1.1 base pairs, and the mean depth of base coverage was 247.0±5.8 reads; 95.23% had \>10‐fold coverage, and 92.5% had \>20‐fold coverage.

The distribution of pathogenic variants is shown in Figure [2](#jah32477-fig-0002){ref-type="fig"}. There were 43 pathogenic variants: 39 missense, 1 deletion, 1 nonsense, and 2 splice site variants. Sarcomere gene variants accounted for 63%, and variants in genes associated with channelopathies accounted for 12%. Overall, *MYH7* was most commonly mutated (n=19, 44%), followed by *TAZ* (n=6, 14%). There was only 1 pathogenic variant in each of the following genes: *MYBPC3, TNNC1, LMNA, ANK2, KCNH2, KCNE3, JUP, HCN4, BMPR1A,* and *TBX5*. Notably, this is the first report of pathogenic variants in *BMPR1A*,*ANK2*, and *TBX5* in LVNC patients. Ten missense variants were identified in *MYBPC3*, but 9 of them were filtered out because of their frequent occurrence (MAF \>0.5%) in the ExAC East Asian or HGVD (Japanese) populations. Consequently, there is a significant difference in the prevalence of variants in *MYH7* and *MYBPC3* in this study, unlike other forms of cardiomyopathy (Table [S3](#jah32477-sup-0001){ref-type="supplementary-material"}).

![Pathogenic gene distribution of left ventricular noncompaction. The number of pathogenic mutations identified in each gene in which at least 1 mutation was identified.](JAH3-6-e006210-g002){#jah32477-fig-0002}

Twenty‐nine novel variants (not detected in 60 706 persons of any race/ethnicity in the ExAC and HGVD databases) were identified in 12 genes: 19 novel variants in sarcomere genes (66%), including 12 *MYH7* variants, and 4 novel variants in *TAZ*. Novel pathogenic variants were also identified in *BMPR1A, HCN4, LMNA, SGCD,* and *TBX5* (Table [S4](#jah32477-sup-0001){ref-type="supplementary-material"}).

In addition, 14 rare variants with MAF\<0.05% in the 2 reference databases were identified in 7 genes (*ANK2, JUP, KCNE3, KCNH2, MYH7*,*MYL2* and *TAZ*; Table [2](#jah32477-tbl-0002){ref-type="table-wrap"}). None of them had been reported previously in East Asian controls in ExAC or HGVD. The odds ratios for the association between the variant and the risk of disease were all significantly \>1.0, and the Fisher exact *P* values were all \<0.05 (Table [2](#jah32477-tbl-0002){ref-type="table-wrap"}). The genic collapsing test revealed that *MYH7* (*P*=1.29E‐17, ranked first) and *TAZ* (*P*=3.48E‐9, ranked second) reached significance (adjusted a or *P*\<1.37×10^−4^), strongly suggesting that variants in these genes contribute to an increased risk of LVNC. All other genes, including *MYBPC3, ANK2, TPM1* and *ACTC1*, did not reach the adjusted α (Table [S5](#jah32477-sup-0001){ref-type="supplementary-material"}).

###### 

The Frequency of Rare Variants in the Control Population Databases

  Gene      Variant       dbSNP         ExAC (All Individuals), %   HGVD, %   Genotype, Case (n=102)   ExAC (East Asian, n=4327)   Risk, OR   Frequency, 95% CI   *P* Value   Classification
  --------- ------------- ------------- --------------------------- --------- ------------------------ --------------------------- ---------- ------------------- ----------- -------------------
  *ANK2*    R321W         rs753032598   0.0025                      ···       1                        0                           127.9      1.08 to + ∞         0.0230      Likely pathogenic
  *JUP*     E146K         rs146581757   0.002                       ···       1                        0                           127.9      1.08 to + ∞         0.0230      Likely pathogenic
  *KCNE3*   R99H          rs121908441   0.0086                      ···       1                        0                           127.9      1.08 to + ∞         0.0230      Pathogenic
  *KCNH2*   A561T         rs199472921   ···                         ···       1                        0                           127.9      1.08 to + ∞         0.0230      Pathogenic
  *MYH7*    R23W          rs730880828   0.0025                      ···       1                        0                           127.9      1.08 to + ∞         0.0230      Likely pathogenic
            L620P         rs199862338   ···                         ···       1                        0                           127.9      1.08 to + ∞         0.0230      Likely pathogenic
            P838L         rs397516153   ···                         ···       1                        0                           127.9      1.08 to + ∞         0.0230      Likely pathogenic
            R904C         rs727503253   0.00082                     ···       1                        0                           127.9      1.08 to + ∞         0.0230      Likely pathogenic
            E1801K        rs397516248   ···                         ···       2                        0                           215.3      8.0 to + ∞          0.0005      Likely pathogenic
            E1914K        rs397516254   ···                         ···       1                        0                           127.9      1.08 to + ∞         0.0230      Likely pathogenic
  *MYL2*    P144fs        rs199567559   0.00082                     ···       1                        0                           127.9      1.08 to + ∞         0.0230      Likely pathogenic
  *TAZ*     G197R         rs132630277   ···                         ···       1                        0                           127.9      1.08 to + ∞         0.0230      Likely pathogenic
            c.109+1G\>C   ···           ···                         ···       1                        0                           127.9      1.08 to + ∞         0.0230      Pathogenic

CI indicates confidence interval; ExAC, Exome Aggregation Consortium database; HGVD, Human Genetic Variation Database; OR, odds ratio.

The Characteristics of Patients With Single or Double Pathogenic Variants {#jah32477-sec-0020}
-------------------------------------------------------------------------

Double heterozygous variants were identified in 4 patients, all of whom presented with congestive heart failure during the fetal or neonatal periods and died before their first birthdays. Of note, none had family history of cardiomyopathy (Table [3](#jah32477-tbl-0003){ref-type="table-wrap"}). Survival analysis revealed that patients with double variants showed the worst prognosis compared with patients with a single variant and without variants (Figure [1](#jah32477-fig-0001){ref-type="fig"}). There were no differences in age of onset, heart failure at diagnosis, LVEF, and family history between the 2 groups (Table [3](#jah32477-tbl-0003){ref-type="table-wrap"}).

###### 

Characteristics of Patients With Single and Double Mutations

                            Single Variant (n=35)   Double Variant (n=4)   *P* Value
  ------------------------- ----------------------- ---------------------- -----------
  Sex, male:female          15:20                   3:1                    0.32
  Age of onset, y           0.5±0.2                 0.001±0.001            0.43
  CHF at diagnosis, n (%)   26 (74.3)               4 (100)                0.56
  Family history, n (%)     12 (34.2)               0                      0.29
  LVEF, %                   36.9±2.2                37.5±3.8               0.93
  LVDD *z* score            1.51±0.19               2.31±0.34              0.19

Double heterozygous variants: *MYH7* and *JUP, MYH7* and *BMPR1A, TPM1* and *SGCD*, and *TAZ* and *KCNE3*. CHF indicates congestive heart failure; LVDD, left ventricular end‐diastolic dimension; LVEF, left ventricular ejection fraction.

### The characteristics of patients with adverse events {#jah32477-sec-0021}

Adverse events were noted in 16 patients: 12 died, 3 underwent HT, and 1 underwent ICD insertion. Among those 16, double heterozygous variants were identified in 4 patients, and single variants were noted in 6, including variants in *TAZ* in 2. No pathogenic variants were identified in the remaining 6 patients (Table [4](#jah32477-tbl-0004){ref-type="table-wrap"}). The majority of patients with adverse events were boys (76%). All of these patients were diagnosed before their first birthday, except 1 who was diagnosed at age 4 years and underwent ICD insertion after 9 months of follow‐up. Five patients were diagnosed during the fetal period, because of severe heart failure and hydrops fetalis, and died soon after birth. The multivariable proportional hazards model showed that congestive heart failure at diagnosis and pathogenic variant were independent risk factors for death, HT, or ICD insertion in all LVNC patients (Table [5](#jah32477-tbl-0005){ref-type="table-wrap"}).

###### 

Characteristics of Patients With Adverse Events

  ID    Gene and Variant                 Age at Onset    Sex   Family History   CHF at Diagnosis   Outcome         Cause of Death
  ----- -------------------------------- --------------- ----- ---------------- ------------------ --------------- ----------------
  234   *SGCD* N99H; *TPM1* D14G         15 d            M     No               Yes                Death           CHF
  274   *TAZ* H176Y; *KCNE3* R99H        Fetus           M     No               Yes                Death           CHF
  280   *MYH7* K542N; *JUP* E146K        Fetus (30 WG)   M     No               Yes                Death           CHF
  342   *MYH7* P838L; *BMPR1A* R284L     1 d             F     No               Yes                Death           CHF
  159   *TAZ* splice donor c.109+1G\>C   2 mo            M     Yes              Yes                Death           CHF
  247   *MYH7* R712H                     Fetus (32 WG)   F     No               Yes                HT              
  312   *ACTC1* T231R                    4 y             M     No               Yes                ICD insertion   
  313   *TAZ* M185V                      1 mo            M     Yes              Yes                HT              
  233   *KCNH2* A561T                    Fetus (25 WG)   M     No               Yes                Death           CHF
  321   *TNNC1* E94A                     4 mo            F     No               No                 HT              
  193   ···                              1 d             M     No               Yes                Death           CHF
  275   ···                              1 d             M     No               Yes                Death           CHF
  294   ···                              1 y             M     No               Yes                Death           CHF
  356   ···                              15 d            M     Yes              Yes                Death           VF
  367   ···                              Fetus           F     Yes              Yes                Death           CHF
  416   ···                              1 mo            M     No               Yes                Death           CHF

CHF indicates congestive heart failure; F, female; HT, heart transplantation; ICD, implantable cardioverter‐defibrillator; M, male; VF, ventricular fibrillation; WG, weeks of gestation.

###### 

Multivariate Analysis of Risk Factors for LVNC

  Variable            Univariable Survival Analysis   Multivariable Survival Analysis                          
  ------------------- ------------------------------- --------------------------------- ---------------------- ---------
  Age at onset, y     3.14 (1.17--8.42)               0.03                              0.47 (0.12--2.61)      0.34
  Family history      1.42 (0.46--4.43)               0.16                              2.08 (0.65--5.97)      0.20
  CHF at diagnosis    19.30 (2.98--20.31)             0.0003                            46.24 (5.39--6097.7)   0.00002
  Genotype positive   3.61 (1.27--10.20)              0.01                              3.22 (1.12--11.22)     0.03

CHF indicates congestive heart failure; CI, confidence interval; HR, hazard ratio; LVNC, left ventricular noncompaction.

### Genotype--phenotype correlations {#jah32477-sec-0022}

Variants found in participants with systolic dysfunction and details of for each participant are shown in Tables [S6](#jah32477-sup-0001){ref-type="supplementary-material"} and [S7](#jah32477-sup-0001){ref-type="supplementary-material"}. Single sarcomere variants were identified in 24 patients, single nonsarcomere variants were found in 11, and double variants were noted in 4 patients (*MYH7* and *JUP*,*MYH7* and *BMPR1A*,*TPM1* and *SGCD*,*TAZ* and *KCNE3*; Table [4](#jah32477-tbl-0004){ref-type="table-wrap"}). There were no differences in age at onset, heart failure onset, LVEF, and family history between the sarcomere and nonsarcomere groups (Table [6](#jah32477-tbl-0006){ref-type="table-wrap"}). Survival analysis showed that the prognosis of patients with nonsarcomere variants was worse than that of patients with sarcomere variants (Figure [3](#jah32477-fig-0003){ref-type="fig"}).

###### 

Characteristics of Patients With Sarcomere and Nonsarcomere Mutations

                            Sarcomere Variant (n=24)   Nonsarcomere Variant (n=11)   *P* Value
  ------------------------- -------------------------- ----------------------------- -----------
  Sex male:female           8:16                       3:8                           0.99
  Age of onset, y           0.7±0.3                    0.15±0.07                     0.26
  CHF at diagnosis, n (%)   15 (62.5)                  10 (91)                       0.12
  Family history, n (%)     6 (34.8)                   6 (54.5)                      0.13
  LVEF, %                   39.4±2.3                   31.8±4.7                      0.11
  LVDD *z* score            1.24±0.2                   2.1±0.4                       0.04

CHF indicates congestive heart failure; LVDD, left ventricular end‐diastolic dimension; LVEF, left ventricular ejection fraction.

![Event‐free survival to the combined end point of death, heart transplantation, and implantable cardioverter‐defibrillator insertion of patients with sarcomere, nonsarcomere (excluding *TAZ* mutations), or *TAZ* mutations.](JAH3-6-e006210-g003){#jah32477-fig-0003}

Because *MYH7* and *TAZ* were predicted to significantly contribute to the risk of LVNC, we compared the characteristics of patients with variants in these genes (Table [7](#jah32477-tbl-0007){ref-type="table-wrap"}). The patients carrying *TAZ* variants displayed a distinct phenotype; all were male infants who presented with congestive heart failure and had worse prognoses. Three had Barth syndrome, 1 with double variants. Overall, 80% of the *TAZ* group had family history of cardiomyopathy; this was much higher than the *MYH7* group. The *TAZ* group presented with higher LVDD *z* scores and lower LVEF than the *MYH7* group. There were no differences in age at onset between the groups. In our study, we found that the clinical manifestation varied significantly in the patients with *MYH7* variants, from no symptoms to severe heart failure. Two patients with double variants of *MYH7* and another gene and 1 patient with *TAZ* and another variant were excluded from the analysis (Table [7](#jah32477-tbl-0007){ref-type="table-wrap"}). Survival analysis showed that the prognosis was significantly worse for patients with *TAZ* variants compared with patients with sarcomere gene variants (*P*=0.03; Figure [3](#jah32477-fig-0003){ref-type="fig"}).

###### 

Characteristics of Patients With *MYH7* or *TAZ* Mutations

                            *MYH7* (N=17)   *TAZ* (N=5)   *P* Value
  ------------------------- --------------- ------------- -----------
  Sex, male:female          5:12            5:0           0.01
  Age at onset, y           0.5±0.4         0.3±0.1       0.71
  CHF at diagnosis, n (%)   10 (58.8)       5 (100)       0.13
  Family history, n (%)     4 (23.5)        4 (80)        0.039
  LVEF, %                   39.8±3.2        20.4±5.6      0.008
  LVDD *z* score            1.07±0.27       3.13±0.36     0.001

Three patients with double mutation of *MYH7* and another gene and 1 patient with *TAZ* and another mutation were excluded. CHF indicates congestive heart failure; LVDD, left ventricular end‐diastolic dimension; LVEF, left ventricular ejection fraction.

Among the patients with nonsarcomere gene variants, 5 carried variants in channelopathy‐related genes: *ANK2*,*KCNE3*,*KCNH2*,*HCN4*, and *JUP*. The ECG of the patient with the *KCNE3* variant showed left bundle‐branch block. ECGs of the patients with *ANK2*,*HCN4* and *LMNA* variants showed normal or nonspecific changes. The patient with the *KCNH2* variant died at 2 weeks after birth due to severe congestive heart failure; however, no specific changes were identified on ECG.

One patient who carried both *MYH7* and *BMPR1A* variants was diagnosed during the fetal period and died after 1 year of follow‐up. We extracted DNA from her postmortem heart and found the same variants in *MYH7* and *BMPR1A* that were detected previously in blood samples (Figure [4](#jah32477-fig-0004){ref-type="fig"}).

![Detection of the *BMPR1A* c.851G\>T (p. R284L) variant in DNA isolated from blood and heart samples of a patient with left ventricular noncompaction.](JAH3-6-e006210-g004){#jah32477-fig-0004}

The variant in *TPM1* appeared de novo (Figure [5](#jah32477-fig-0005){ref-type="fig"}A), as neither parent nor a brother carried this variant.

![A, De novo variant of *TPM1* c.41A\>G (p. D14G) in an LVNC family. B, Familial LVNC and Ebstein anomaly associated with the *MYH7* c.1085T\>G p.Met362Arg. LVNC, left ventricular noncompaction.VSD, ventricular septal defect.](JAH3-6-e006210-g005){#jah32477-fig-0005}

A variant in *MYH7*, c.1085T\>G (p. Met362Arg), was identified in a family with LVNC and Ebstein anomaly (Figure [5](#jah32477-fig-0005){ref-type="fig"}B); we previously reported this variant[14](#jah32477-bib-0014){ref-type="ref"} using a candidate gene approach. However, no additional pathogenic variants, inherited from the unaffected mother, were identified in the offspring with Ebstein anomaly that could account for the phenotypic difference between the father and the children.

Discussion {#jah32477-sec-0023}
==========

In summary, use of a focused NGS strategy in a large cohort of 102 LVNC patients revealed a wide and specific spectrum of genetic variations and a high incidence of novel pathogenic variants in LVNC patients. In addition, we found poorer prognosis in the patients with pathogenic variants, and the detection of a pathogenic variant was an independent risk factor for death, HT, and ICD insertion.

There appears to be a distinct spectrum of gene variants in Japanese patients with LVNC. Variants in *MYH7* appear to be a significant cause of LVNC, accounting for almost half of the pathogenic variants identified, whereas the prevalence of *MYBPC3* variants were unexpectedly low. Furthermore, collapsing analysis confirmed that *MYH7* variants increase the risk of developing LVNC, whereas *MYBPC3* variants did not. This genetic spectrum is quite different from previous studies in patients with hypertrophic cardiomyopathy or dilated cardiomyopathy (Table [S3](#jah32477-sup-0001){ref-type="supplementary-material"}). In patients with hypertrophic cardiomyopathy, mutations in *MYBPC3* and *MYH7* are most commonly detected.[17](#jah32477-bib-0017){ref-type="ref"}, [18](#jah32477-bib-0018){ref-type="ref"}, [19](#jah32477-bib-0019){ref-type="ref"}, [20](#jah32477-bib-0020){ref-type="ref"}, [21](#jah32477-bib-0021){ref-type="ref"} In contrast, in patients with dilated cardiomyopathy, variants in titin are most commonly detected, whereas variants in *MYH7* and *MYBPC3* account for \<1%.[22](#jah32477-bib-0022){ref-type="ref"} Although the majority of the LVNC patients presented with the same phenotypic characteristics as patients with dilated cardiomyopathy, heart failure, dilated left ventricle, and decreased LVEF, they have a very different genetic etiology.

In the patients with *MYH7* variants, we found that there was a broad spectrum in clinical manifestation, ranging from no symptoms to severe heart failure, as reported previously.[9](#jah32477-bib-0009){ref-type="ref"}, [23](#jah32477-bib-0023){ref-type="ref"} The mechanisms by which *MYH7* variants induce cardiomyopathy are still unclear. Han et al identified abnormal long noncoding RNA transcripts from the *MYH7* locus that may cause cardiomyopathy.[24](#jah32477-bib-0024){ref-type="ref"} Fang et al found that methylation levels in the promoters of *MYH7* may play an important role in regulating embryonic cardiomyocyte gene expression, morphology, and function.[25](#jah32477-bib-0025){ref-type="ref"}

Although previous studies have reported several *MYBPC3* variants in LVNC patients,[9](#jah32477-bib-0009){ref-type="ref"} we identified only 1 pathogenic variant in *MYBPC3,* in a 3‐year‐old girl. She remained asymptomatic during the 5 years of follow‐up. Hypertrophic cardiomyopathy patients with *MYBPC3* mutations also present with reduced or late penetrance, often during the fifth decade of life.[26](#jah32477-bib-0026){ref-type="ref"} Therefore, ongoing follow‐up is warranted, even in an asymptomatic patient with LVNC. Among the other sarcomere genes, *ACTC1, TNNT2*,[27](#jah32477-bib-0027){ref-type="ref"} and *TPM1* mutations are less common in LVNC than other cardiomyopathies. *ACTC1* was first reported to be associated with LVNC in 2008,[8](#jah32477-bib-0008){ref-type="ref"} and we reported 2 *TPM1* mutations, as well as 2 *ACTC1* mutations, in LVNC patients in 2011.[28](#jah32477-bib-0028){ref-type="ref"}

*TAZ* variants may also increase the risk for LVNC, and survival analysis showed worse prognosis in patients with these variants. *TAZ* was identified in 1996 as the causative gene for Barth syndrome,[29](#jah32477-bib-0029){ref-type="ref"} and LVNC is frequently described in patients with Barth syndrome.[30](#jah32477-bib-0030){ref-type="ref"}, [31](#jah32477-bib-0031){ref-type="ref"}, [32](#jah32477-bib-0032){ref-type="ref"} However, half of the patients with *TAZ* variants identified in this study did not show any other manifestations of Barth syndrome. Consequently, male infants with severe heart failure should be considered for genetic analysis, including *TAZ*, even if they do not show any signs of Barth syndrome. In an animal model, tafazzin deficiency leads to ventricular noncompaction and early lethality.[33](#jah32477-bib-0033){ref-type="ref"} Wang et al used induced pluripotent stem cell--derived cardiomyocytes and elucidated that *TAZ* deficiency in Barth syndrome impairs sarcomere assembly and contractile stress generation. *TAZ* deficiency may increase reactive oxygen species production, which may cause features of Barth syndrome.[34](#jah32477-bib-0034){ref-type="ref"}

Among channelopathy‐related genes, this is the first report of an *ANK2* variant in LVNC. *ANK2* variants have previously been associated with cardiac arrhythmia syndrome or long QT syndrome and were recently found in hypertrophic cardiomyopathy patients.[35](#jah32477-bib-0035){ref-type="ref"} Although none of our patients who carried variants in arrhythmia‐associated genes presented with severe arrhythmias, given the high risk of arrhythmia associated with these genes, close monitoring and consideration of ICD implantation to prevent sudden cardiac death is recommended.[36](#jah32477-bib-0036){ref-type="ref"}

The variant in *BMPR1A* is also the first reported in a patient with LVNC. BMPs (Bone morphogenetic proteins) are members of the transforming growth factor family that play critical roles in cardiac development. BMP signaling is required in the myocardium of the atrioventricular canal for proper atrioventricular junction development, and an anomaly in *BMPR1A*‐mediated signaling may contribute to the development of cardiac hypertrophy and embryonic heart failure.[37](#jah32477-bib-0037){ref-type="ref"}, [38](#jah32477-bib-0038){ref-type="ref"}, [39](#jah32477-bib-0039){ref-type="ref"} In our study, the patient who carried both *MYH7* and *BMPR1A* variants presented with bradycardia as a fetus and died of heart failure at 1 year of age. Although most patients with a single variant of *MYH7* did not develop severe manifestations, the *BMPR1A* variant may act as genetic modifier and contribute to fetal heart failure. Functional studies of the *BMPR1A* variant are now under way in animal models.

The variant in *TBX5* also represents the first in this gene in a patient with LVNC, as shown in the present study. Both *TBX5* and *TBX20* of the T‐box family are important for maintenance of mature cardiomyocyte function.[40](#jah32477-bib-0040){ref-type="ref"}, [41](#jah32477-bib-0041){ref-type="ref"} Kodo et al showed that proper activation of TGF‐β (transforming growth factor β) signaling in the embryonic heart is required to ensure compact layer remodeling. They used patient‐specific induced pluripotent stem cell--derived cardiomyocytes generated from an LVNC patient who carried a *TBX20* mutation and found abnormal TGF‐β signaling.[41](#jah32477-bib-0041){ref-type="ref"} Functional studies of the *TBX5* mutation are also under way in animal models.

The focused NGS strategy allows for rapid molecular diagnosis at a reasonable cost. In this study, we implemented strict pathogenic variant identification criteria that could prevent misinterpretation of the variants.[42](#jah32477-bib-0042){ref-type="ref"} We found that patients with pathogenic variants showed high morbidity and mortality. Furthermore, patients with double heterozygous variants presented with severe phenotypes during the fetal or neonatal periods and had very poor prognosis, as reported previously.[43](#jah32477-bib-0043){ref-type="ref"} The role of double variants in determining the severity of disease remains unknown and cannot be evaluated using in silico predictive algorithms at the present time. Our study suggests that comprehensive screening of multiple disease‐causing genes is necessary to identify high‐risk patients with LVNC, for whom earlier treatment strategies toward HT or ICD implantation should be considered.

Limitations {#jah32477-sec-0024}
-----------

In this study, some parental samples were not available, limiting segregation analysis and the ability to determine whether variants were inherited or arose de novo; none of these patients reported family history, and the parents were healthy and without evidence of cardiomyopathy by ECG and echocardiography. In addition, we chose NGS panels of genes known to be associated with cardiac phenotypes or development; therefore, variants in novel genes would have been missed. Our sequencing approach lacked of ability to assess copy number and structural variants. Whole‐exome or ‐genome sequencing in this cohort might have uncovered additional variants, including copy number variations and structural variants, but at considerably higher cost. Genetic analysis using NGS is considered to have some limitations. Recent studies showed extended genetic noise (false positive), particularly within cardiac disease--associated genes, even if these variants were rare. Guidelines recommend that several in silico analyses be used to evaluate variants without familial and/or experimental evidence of pathogenicity because most algorithms used for missense variant prediction are only 65--80% accurate for known disease variants.[12](#jah32477-bib-0012){ref-type="ref"}, [44](#jah32477-bib-0044){ref-type="ref"} Further research will be focus on the mechanism presented in animal models and analysis of induced pluripotent stem cells developed from patients with known gene variants to identify the mechanisms that underlie the abnormal development of the failed compacted layer during the embryonic period.

Conclusion {#jah32477-sec-0025}
==========

A focused NGS approach revealed a wide and distinct spectrum of gene variants in a large cohort of patients with LVNC. Patients with pathogenic variants showed early age at onset and decreased LVEF. The identification of a pathogenic variant was an independent risk factor for death, HT, or ICD insertion. Survival analysis showed poorer prognosis in the patients with pathogenic variants, especially patients with multiple or *TAZ* variants. Our study suggests that comprehensive screening of multiple disease‐causing genes is necessary to identify high‐risk patients with LVNC, for whom earlier treatment strategies toward HT or ICD implantation should be considered.
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